Biologic therapies for the treatment of chronic spontaneous urticaria (CSU) are potentially underutilized in veterans within the United States, according to a study published in the Journal of the American Academy of Dermatology. The retrospective cohort study included more than 26,000 veterans who were a mean age of 54.9 years. Most of the participants were men (76.4%) and White (60.8%). Veterans were eligible to be evaluated if they were at least 18 years of age and had 2 or more urticaria diagnoses or 1 urticaria and 1 angioedema diagnosis at least 6 weeks prior. ...
Disparities in Chronic Spontaneous Urticaria
Advertisement
Around 70% of patients presenting to the emergency department for urticaria received diphenhydramine.
The Urticaria Activity Score is commonly utilized in chronic spontaneous urticaria clinical trials.
Acupuncture therapy as an adjunct to omalizumab was found to improve disease control and quality of life.
Patients with CSU who utilized a digital telehealth platform reported improved quality-of-life scores.
Urticaria raises the risk of ADHD, bipolar disorder, and schizophrenia.
Omalizumab is a safe and effective long-term treatment for CSU.
Nearly 50% of patients with chronic spontaneous urticaria are atopic, with atopy linked to increased risk of dermatographism,
A recent study demonstrated significant associations between acute urticaria and cardiovascular comorbidities.
Autoimmune mast cell activation test shows promise as a diagnostic tool for chronic spontaneous urticaria.
Omalizumab treatment in CSU patients leads to significant changes in T-cell subpopulations.
Patients with both asthma and chronic urticaria have more severe allergic responses.
Omalizumab effectively reduces symptoms in CSU patients, but a 300 mg dose is recommended.
A systematic review found that biologic omalizumab is cost-effective for treating H1 antihistamine–refractory CSU.
According to a recent study, serum zonulin levels had a significant correlation with the urticaria activity score
Advertisement
Expert Interviews
Urban Health Today reports on clinical news and policy updates that directly impact urban health care providers and their patients.
Get research and expert insights straight to your inbox.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.